Previous 10 | Next 10 |
The Alzheimer's community got a boost at the end of October when Biogen (NASDAQ: BIIB) announced it would file for approval from the U.S. Food and Drug Administration for aducanumab, its Alzheimer's disease drug. This caught patients and investors off guard since Biogen scrapped the pro...
Data Presented at the 2019 American College of Allergy, Asthma and Immunology Annual Meeting Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced new data that further investigates the long-term safety and efficacy of TAKHZYRO ® ...
Takeda Pharmaceutical Company ( TAK +1.2% ) announces positive results from a Phase 3 clinical trial, TOURMALINE-MM4 , evaluating Ninlaro (ixazomib) as first-line maintenance therapy in adult multiple myeloma patients who have not received stem cell transplantation. The study met the pr...
With 57 consecutive years of dividend raises, Coca-Cola (NYSE: KO) has long been a darling for dividend investors. Its iconic brands, including Coca-Cola, Diet Coke, Fanta, Sprite, Minute Maid, and Powerade, dominate markets worldwide. As consumer tastes have changed away from sugary...
− The manufacturing plant opening marks an important milestone for Takeda’s mission to tackle the global threat of dengue − The site will be utilized for formulation, fill, finish and secondary packaging of Takeda’s dengue vaccine candidate ...
− Ongoing Phase 1/2a Study of CD19 CAR-NK with Pivotal Study Expected to Enroll Patients in 2021 − Potential to be the First CAR Cell Therapy Approved for Outpatient Administration The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Comp...
Transaction further accelerates deleveraging Strengthens alignment of Growth & Emerging Markets Business Unit portfolio with Takeda’s global business areas Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has ent...
The Institute for Clinical and Economic Review (ICER), a Boston-based nonpartisan nonprofit with no policy-making role, has emerged as a major influencer on pricing by drugmakers. More news on: Sanofi, Regeneron Pharmaceuticals, Inc., Amgen Inc., Healthcare stocks news, News on ETFs, ...
Takeda Pharmaceutical Co. Ltd. (TAK) Q3 2019 Results Earnings Conference Call October 31, 2019 08:00 AM ET Company Participants Takashi Okubo - IR Christophe Weber - CEO Constantine Saroukos - CFO Andrew Plump - President of R&D Conference Call Participants Josh bro...
Axonics Modulation Technologies (NASDAQ: AXNX ) initiated with Overweight rating at Piper Jaffray. More news on: Axonics Modulation Technologies, Inc., Homology Medicines, Inc., Sarepta Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
− If Approved in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless of Biomarker Status in Over a Decade − Positive Opinion Based on Results from a Phase 3 Clinical Trial Which Demonstrated Significan...
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO-2 Phase III clinical trial — ...
Neurocrine Biosciences Inc (NASDAQ:NBIX) revealed on Tuesday topline data for its Phase 2 SAVITRI study of NBI-1065845 in adult subjects with maj...